Platelet glycoprotein receptors and vascular sub-endothelial matrix proteins

The vascular sub-endothelium matrix and platelet glycoprotein receptors represent a multi-component system essential for hemostasis and the pathogenesis of arterial thrombosis (StatPearls, 2023). Upon vascular injury, the sub-endothelial matrix—comprising proteins like collagen and von Willebrand factor (vWF)—is exposed to blood flow, initiating platelet recruitment (NCBI, 2022). Platelets adhere to these ligands via specific surface receptors: the Glycoprotein Ib-IX-V complex binds vWF for initial tethering, while Glycoprotein VI (GPVI) and integrin α2β1 bind collagen to provide stable adhesion and activation (UniProt, 2024). This activation leads to the conformational change of integrin αIIbβ3 (GPIIb/IIIa), which mediates platelet aggregation by binding fibrinogen and vWF (Journal of Thrombosis and Haemostasis, 2021). Therapeutic agents targeting this system include GPIIb/IIIa inhibitors like abciximab and vWF-targeting nanobodies like caplacizumab, which are used to prevent thrombotic complications in acute coronary syndromes and microangiopathies (FDA, 2019). The primary clinical challenge associated with modulating this system is the narrow therapeutic window between preventing pathological thrombosis and inducing significant bleeding (PubMed, 2020).

Other names

Platelet-subendothelium interaction systemPlatelet adhesion receptorsGlycoprotein Ib-IX-V complexGlycoprotein VIIntegrin alpha-IIb/beta-3Integrin alpha-2/beta-1von Willebrand factorSubendothelial collagen

Inhibition of platelet adhesion to the vascular sub-endothelium and subsequent aggregation by blocking glycoprotein receptors or their matrix ligands.